In this edition, lung cancer risk is high among smokers for whom screening is not recommended; the role of circulating tumor DNA in lung cancer detection and treatment is 'exciting' for field; a subset of patients with lung cancer have poor response to COVID-19 vaccines, and more.
Read the full coverage here:
Lung cancer risk high among smokers for whom screening is not recommended
Role of circulating tumor DNA in lung cancer detection, treatment 'exciting' for field
Subset of patients with lung cancer have poor response to COVID-19 vaccines
Low area-level income, education linked to higher odds of late-stage lung cancer diagnosis
Phase 3 trial of Onivyde for small cell lung cancer misses endpoint
References:
Faselis C, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.2952.
Gupta A, et al. Cancer. 2022;doi:10.1002/cncr.34327.
Healio Interview
Valanparambil RM, et al. J Clin Oncol. 2022;doi:10.1200/JCO.21.02986.
